[{"address1": "7707 Gateway Boulevard", "address2": "Suite 140", "city": "Newark", "state": "CA", "zip": "94560", "country": "United States", "phone": "510 474 0170", "website": "https://www.protagonist-inc.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.", "fullTimeEmployees": 126, "companyOfficers": [{"maxAge": 1, "name": "Dr. Dinesh V. Patel Ph.D.", "age": 67, "title": "CEO, President, Secretary & Director", "yearBorn": 1957, "fiscalYear": 2023, "totalPay": 1026472, "exercisedValue": 0, "unexercisedValue": 10583697}, {"maxAge": 1, "name": "Mr. Asif  Ali", "age": 50, "title": "Executive VP & Chief Financial Officer", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 631042, "exercisedValue": 0, "unexercisedValue": 285755}, {"maxAge": 1, "name": "Dr. Suneel K. Gupta Ph.D.", "age": 65, "title": "Executive VP of Clinical Development", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 719206, "exercisedValue": 0, "unexercisedValue": 2986052}, {"maxAge": 1, "name": "Mr. Mohammad  Masjedizadeh Ph.D.", "title": "Executive VP & Chief Technical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Newman  Yeilding", "title": "EVP, Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew M. Gosling J.D.", "age": 53, "title": "Executive VP & General Counsel", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Carena  Spivey", "title": "Head of HR & Senior VP of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ashok  Bhandari Ph.D.", "age": 60, "title": "Executive VP & Chief Drug Discovery and Preclinical Development Officer", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Carter J. King", "age": 53, "title": "Executive Vice President of Business Development", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Abha  Bommireddi", "title": "Executive Vice President of Portfolio & Program Management", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 7, "overallRisk": 8, "governanceEpochDate": 1740787200, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 49.44, "open": 49.47, "dayLow": 48.795, "dayHigh": 50.435, "regularMarketPreviousClose": 49.44, "regularMarketOpen": 49.47, "regularMarketDayLow": 48.795, "regularMarketDayHigh": 50.435, "payoutRatio": 0.0, "beta": 2.33, "trailingPE": 11.555555, "forwardPE": -34.18182, "volume": 647355, "regularMarketVolume": 647355, "averageVolume": 956363, "averageVolume10days": 1227850, "averageDailyVolume10Day": 1227850, "bid": 48.72, "ask": 49.02, "bidSize": 4, "askSize": 3, "marketCap": 3000464640, "fiftyTwoWeekLow": 24.22, "fiftyTwoWeekHigh": 60.6, "priceToSalesTrailing12Months": 6.9066224, "fiftyDayAverage": 42.4954, "twoHundredDayAverage": 41.3418, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 2592417024, "profitMargins": 0.63344, "floatShares": 49266417, "sharesOutstanding": 61384300, "sharesShort": 5129814, "sharesShortPriorMonth": 4221220, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.0836, "heldPercentInsiders": 0.01381, "heldPercentInstitutions": 1.05284, "shortRatio": 3.53, "shortPercentOfFloat": 0.0847, "impliedSharesOutstanding": 61533300, "bookValue": 11.064, "priceToBook": 4.417932, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "earningsQuarterlyGrowth": 3.817, "netIncomeToCommon": 275188000, "trailingEps": 4.23, "forwardEps": -1.43, "enterpriseToRevenue": 5.967, "enterpriseToEbitda": 10.22, "52WeekChange": 0.72843003, "SandP52WeekChange": 0.06429911, "quoteType": "EQUITY", "currentPrice": 48.88, "targetHighPrice": 82.0, "targetLowPrice": 45.0, "targetMeanPrice": 69.1, "targetMedianPrice": 69.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 418912992, "totalCashPerShare": 6.824, "ebitda": 253668992, "totalDebt": 10866000, "quickRatio": 12.393, "currentRatio": 12.482, "totalRevenue": 434432992, "debtToEquity": 1.609, "revenuePerShare": 7.056, "returnOnAssets": 0.28662002, "returnOnEquity": 0.54386, "grossProfits": 434432992, "freeCashflow": 65107876, "operatingCashflow": 184152000, "earningsGrowth": 3.513, "revenueGrowth": 1.844, "grossMargins": 1.0, "ebitdaMargins": 0.58391, "operatingMargins": 0.74297994, "financialCurrency": "USD", "symbol": "PTGX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Protagonist Therapeutics, Inc.", "longName": "Protagonist Therapeutics, Inc.", "marketState": "CLOSED", "regularMarketChangePercent": -1.1326813, "regularMarketPrice": 48.88, "corporateActions": [], "postMarketTime": 1743194053, "regularMarketTime": 1743192001, "hasPrePostMarketData": true, "exchange": "NGM", "messageBoardId": "finmb_129263324", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "firstTradeDateMilliseconds": 1470922200000, "postMarketChangePercent": 0.0, "postMarketPrice": 48.88, "postMarketChange": 0.0, "regularMarketChange": -0.55999756, "regularMarketDayRange": "48.795 - 50.435", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 956363, "fiftyTwoWeekLowChange": 24.660002, "fiftyTwoWeekLowChangePercent": 1.0181669, "fiftyTwoWeekRange": "24.22 - 60.6", "fiftyTwoWeekHighChange": -11.719997, "fiftyTwoWeekHighChangePercent": -0.1933993, "fiftyTwoWeekChangePercent": 72.843, "earningsTimestamp": 1740144600, "earningsTimestampStart": 1746475200, "earningsTimestampEnd": 1746820800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": 4.23, "epsForward": -1.43, "epsCurrentYear": -1.22625, "priceEpsCurrentYear": -39.861366, "fiftyDayAverageChange": 6.3846016, "fiftyDayAverageChangePercent": 0.15024218, "twoHundredDayAverageChange": 7.5382004, "twoHundredDayAverageChangePercent": 0.18233846, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.6 - Buy", "cryptoTradeable": false, "displayName": "Protagonist Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-03-29"}]